Breaking News
Grand Theft World Podcast 273 | Goys 'R U.S. with Guest Rob Dew
Anchorage was the Receipt: Europe is Paying the Price… and Knows it.
The Slow Epstein Earthquake: The Rupture Between the People and the Elites
Israeli Prime Minister, Netanyahu will meet with Trump on Wednesday and deliver instructions...
Top Tech News
Drone-launching underwater drone hitches a ride on ship and sub hulls
Humanoid Robots Get "Brains" As Dual-Use Fears Mount
SpaceX Authorized to Increase High Speed Internet Download Speeds 5X Through 2026
Space AI is the Key to the Technological Singularity
Velocitor X-1 eVTOL could be beating the traffic in just a year
Starlink smasher? China claims world's best high-powered microwave weapon
Wood scraps turn 'useless' desert sand into concrete
Let's Do a Detailed Review of Zorin -- Is This Good for Ex-Windows Users?
The World's First Sodium-Ion Battery EV Is A Winter Range Monster
China's CATL 5C Battery Breakthrough will Make Most Combustion Engine Vehicles OBSOLETE
Oligodendrocyte progenitor cells repair damaged spine in humans...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research.
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
As part of a multi-center trial, doctors at Keck Medical Center at the University of Southern California, employing Asterias Biotherapeutics' AST-OPC1 experimental treatment, injected 10 million oligodendrocyte progenitor cells (OPCs) into the damaged spine of Kristopher (Kris) Boesen a 21 year-old California man who was paralyzed from the neck down after suffering a traumatic cervical spine injury in an automobile accident on March 6th, 2016.